Gets in its own way. - Director bei Merck: Mitarbeiterbewertung

2,0
19. Nov. 2014
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

People try, hopeful for change, but management isn't equipped to enable it. (and that's my "pro")

Kontras

Merger with Schering-Plough after 5+ years is still lingering with an "us"/"them" perspective. For new employees, beware of the "this is how we've always done it" approach, even though management purports the opposite. Proof that just because it's in a powerpoint deck doesn't make it so.

Mehr Bewertungen zu Merck entdecken

5,0
30. Juni 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Excellent company to work with.

Kontras

No cons encountered so far

4,0
30. Juni 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Great benefits like medical/dentist/vision, pension, stock option, 401k match. Co workers are excellent, pretty good on site symposiums, lot of diversity clubs/activities. Innovation is extremely welcomed. Diversity in research portfolio. AI/ML is heavily invested to make databases more efficient.

Kontras

Micro managing, especially within the biologics department, potentially others. Promotions are limited, and pay bump is poor. Company invests too much in buying companies rather than keeping talent - lay offs let go of great talented people. Merck is afraid of investing into exploratory biology and doesn’t take risk - they even admit they would rather see other companies clinical data or R&D data rather than taking a risk. Although it’s slow going in building new software, current databases are slow and needs much improvement. Extremely poor work/life balance.

Bewertungen anzeigen nach: Hilfreich|Sterne|Datum|Alle